Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN023 vs HRIG in Post Exposure Prophylaxis of Rabies
NCT03961555Phase 2Completed
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zamerovimab + mazorelvimab in rabies, sponsored by Xingmeng Biopharmaceutical. Started Sep 2019; status: completed.
02
Drugs
zamerovimab + mazorelvimab
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03961555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961555.